Nutriband signs trademark licensing agreement for Bitrex® brand denatonium benzoate, the most bitter substance in the world, as an aversive…
European Commission grants conditional marketing authorization for Iqirvo® (elafibranor), first-in-class new treatment for primary biliary cholangitis (PBC), a rare liver…
Bagsværd, Denmark, 20 September 2024 – Novo Nordisk today announced headline results from a phase 2a clinical trial with monlunabant,…
MIAMI, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress” or “Company”), an innovative biopharmaceutical company focused…
THE WOODLANDS, TX, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical…
-Trial to focus on particularly vulnerable subset of patients, following strong clinician interest in use of the Alpha DaRT in…
Upon authorization by the European Commission, the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age…
OPUVIZ™, a biosimilar referencing Eylea1 (aflibercept), is Samsung Bioepis and Biogen’s second ophthalmology biosimilar to be recommended for marketing authorization…
Recommendation based on a Phase 3 trial showing a significantly greater proportion of children on Dupixent achieved histological remission compared…
Dupixent recommended for EU approval by the CHMP to treat eosinophilic esophagitis in children as young as 1 year old…